Biogen Names Priya Singhal as Executive Vice President, Head of Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Biogen Names Priya Singhal as Executive Vice President, Head of Development
January 6, 2023 7:05 AM EST
Biogen (NASDAQ: BIIB) is gaining 1% in pre-open trade ahead of lecanemab's accelerated approval PDUFA today.
After the close, analysts at RBC Capital noted that Eisai's patient assistance hotline for Leqembi/lecanemab just became active suggesting "increased likelihood an approval."
...
More
January 5, 2023 4:11 PM EST
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $362.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "Sometime between late this morning and now, Eisai's patient assistance hotline for Leqembi/lecanemab just became active, whereas for the last several weeks the phone number (which we obtained via Google search) had not been... More
January 5, 2023 11:50 AM EST
Biogen's (NASDAQ: BIIB) lecanemab's accelerated approval PDUFA is slated for Friday, January 6, and analysts have been weighing in with their view heading into the date.
Jefferies analyst Michael Yee, who has a Buy rating and a $350 price target on Biogen shares, said in a note to clients that the "consensus assumes clean approval, which is reasonable though mostly... More
